AKTX Celsus Therapeutics PLC

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Live moderated webcast on Thursday, September 4th at 4:00 PM ET

Access the event

BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that it will participate in the on Thursday, September 4, 2025 at 4:00 PM ET.

As part of the event, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will provide a corporate overview and discuss its innovative payload platform fueling a pipeline of next-generation ADCs designed with novel immuno-oncology payloads to address a wide range of cancer tumor targets. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.

The will be available in the section of the Company’s website (). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome modulator designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing modulator has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. Using this novel payload, Akari has the ability to generate multiple ADC molecules based on the desired application to a range of cancer targets of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.

For more information about the Company, please visit and connect on and .

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

908-824-0775



EN
03/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celsus Therapeutics PLC

 PRESS RELEASE

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Globa...

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the being held from September 8-10, 2025 in New York, NY.  In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of ...

 PRESS RELEASE

Akari Therapeutics to Participate in the Virtual Investor Closing Bell...

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that it will participate in the on Thursday, September 4, 2025 at 4:00 PM ET. As part of the event, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will...

 PRESS RELEASE

Akari Therapeutics to Present at the Webull Financial Corporate Connec...

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech Live video webcast on Tuesday, August 19th at 2:00 PM ET BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announced that it will present at the being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Tuesday, August 19, 2025 at 2:00 PM ET Presenter: Abizer Ga...

 PRESS RELEASE

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari’s commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1 BOSTON and LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in...

 PRESS RELEASE

Akari Therapeutics Continues Key Research on its Novel Antibody Drug C...

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed target Emerging new preclinical data on impact of PH1 payload against a key oncogenic driver is expected before year-end BOSTON and LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Pl...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch